Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Brca1 C-terminal (BRCT) domains are a common protein-protein interaction motif in proteins involved in the DNA damage response and DNA repair. The DNA-damage response protein
53BP1
has two BRCT domains that bind to the DNA-binding domain of
p53
. The
53BP1
tandem-BRCT region is homologous to the tandem-BRCT region of Brca1, which is involved in double-strand break repair and homologous recombination and which binds BACH1, a member of the DEAH helicase family. Here we report the structures of a human
53BP1
-
p53
complex and of the rat Brca1 BRCT repeats. The
53BP1
-
p53
structure shows that the two BRCT repeats are arranged tandemly and pack extensively through an interface that also involves the inter-repeat linker. The first BRCT repeat and the linker together bind
p53
on a region that overlaps with the DNA-binding surface of
p53
and involves
p53
residues that are mutated in cancer and are important for DNA binding. Comparison with the structure of the tandem-BRCT region of Brca1 shows a remarkable conservation of the repeat arrangement and of the inter-BRCT repeat interface. Analysis of human BRCA1 tumor-derived mutations and conservation identifies a potential protein-binding site that we show through mutagenesis is involved in BACH1 binding. The BACH1-binding region of Brca1 consists of a unique insertion in the first BRCT repeat and the inter-repeat linker and is analogous to the region of
53BP1
that binds
p53
.
...
PMID:Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. 1187 78
The BRCT (BRCA1 C-terminus) is an evolutionary conserved protein-protein interacting module found as single, tandem or multiple repeats in a diverse range of proteins known to play roles in the DNA-damage response. The BRCT domains of
53BP1
bind to the tumour suppressor
p53
. To investigate the nature of this interaction, we have determined the crystal structure of the
53BP1
BRCT tandem repeat in complex with the DNA-binding domain of
p53
. The structure of the
53BP1
-
p53
complex shows that the BRCT tandem repeats pack together through a conserved interface that also involves the inter-domain linker. A comparison of the structure of the BRCT region of
53BP1
with the BRCA1 BRCT tandem repeat reveals that the interdomain interface and linker regions are remarkably well conserved.
53BP1
binds to
p53
through contacts with the N-terminal BRCT repeat and the inter-BRCT linker. The
p53
residues involved in this binding are mutated in cancer and are also important for DNA binding. We propose that BRCT domains bind to cellular target proteins through a conserved structural element termed the 'BRCT recognition motif'.
...
PMID:Crystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor. 1211 May 97
A complex of the DNA-binding domain of the tumour suppressor
p53
bound to the BRCT domains of the p53-binding protein (
53BP1
) has been prepared and purified. Single crystals have been obtained using the microbatch technique with polyethylene glycol 4 kDa and ammonium sulfate. Crystals diffract X-rays to beyond 2.3 A and belong to the space group P2(1)2(1)2(1). Several complete data sets have been collected from a number of crystals, each with different unit-cell parameters. Partial structures have been produced by successful placement of two copies of the
p53
core region into the asymmetric unit. There is clear evidence for the binding protein and a complete structure determination is under way.
...
PMID:Purification, crystallization and preliminary X-ray analysis of the BRCT domains of human 53BP1 bound to the p53 tumour suppressor. 1235 27
53BP1
binds to the
tumor suppressor protein p53
and has a potential role in DNA damage responses. We used small interfering RNA (siRNA) directed against
53BP1
in mammalian cells to demonstrate that
53BP1
is a key transducer of the DNA damage checkpoint signal.
53BP1
was required for
p53
accumulation, G2-M checkpoint arrest, and the intra-S-phase checkpoint in response to ionizing radiation.
53BP1
played a partially redundant role in phosphorylation of the downstream checkpoint effector proteins Brca1 and Chk2 but was required for the formation of Brca1 foci in a hierarchical branched pathway for the recruitment of repair and signaling proteins to sites of DNA damage.
...
PMID:53BP1, a mediator of the DNA damage checkpoint. 1236 21
53BP1
is a conserved nuclear protein that is implicated in the DNA damage response. After irradiation,
53BP1
localizes rapidly to nuclear foci, which represent sites of DNA double strand breaks, but its precise function is unclear. Using small interference RNA (siRNA), we demonstrate that
53BP1
functions as a DNA damage checkpoint protein.
53BP1
is required for at least a subset of ataxia telangiectasia-mutated (ATM)-dependent phosphorylation events at sites of DNA breaks and for cell cycle arrest at the G2-M interphase after exposure to irradiation. Interestingly, in cancer cell lines expressing mutant p53,
53BP1
was localized to distinct nuclear foci and ATM-dependent phosphorylation of Chk2 at Thr 68 was detected, even in the absence of irradiation. In addition, Chk2 was phosphorylated at Thr 68 in more than 50% of surgically resected lung and breast tumour specimens from otherwise untreated patients [corrected]. We conclude that the constitutive activation of the DNA damage checkpoint pathway may be linked to the high frequency of
p53
mutations in human cancer, as
p53
is a downstream target of Chk2 and ATM.
...
PMID:53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. 1246 29
Activation of the ataxia telangiectasia mutated (ATM) kinase triggers diverse cellular responses to ionizing radiation (IR), including the initiation of cell cycle checkpoints. Histone H2AX,
p53
binding-protein 1 (
53BP1
) and Chk2 are targets of ATM-mediated phosphorylation, but little is known about their roles in signalling the presence of DNA damage. Here, we show that mice lacking either H2AX or
53BP1
, but not Chk2, manifest a G2-M checkpoint defect close to that observed in ATM(-/-) cells after exposure to low, but not high, doses of IR. Moreover, H2AX regulates the ability of
53BP1
to efficiently accumulate into IR-induced foci. We propose that at threshold levels of DNA damage, H2AX-mediated concentration of
53BP1
at double-strand breaks is essential for the amplification of signals that might otherwise be insufficient to prevent entry of damaged cells into mitosis.
...
PMID:DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. 1246 29
53BP1
is a p53 binding protein of unknown function that binds to the central DNA-binding domain of
p53
. It relocates to the sites of DNA strand breaks in response to DNA damage and is a putative substrate of the ataxia telangiectasia-mutated (ATM) kinase. To study the biological role of
53BP1
, we disrupted the
53BP1
gene in the mouse. We show that, similar to ATM(-/-) mice,
53BP1
-deficient mice were growth retarded, immune deficient, radiation sensitive, and cancer prone.
53BP1
(-/-) cells show a slight S-phase checkpoint defect and prolonged G(2)/M arrest after treatment with ionizing radiation. Moreover,
53BP1
(-/-) cells feature a defective DNA damage response with impaired Chk2 activation. These data indicate that
53BP1
acts downstream of ATM and upstream of Chk2 in the DNA damage response pathway and is involved in tumor suppression.
...
PMID:p53 Binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. 1264 Jan 36
NFBD1/MDC1 (mediator of DNA damage checkpoint 1) is a nuclear factor with an amino-terminal FHA (forkhead-associated) domain and a tandem repeat of BRCT (breast cancer susceptibility gene-1 carboxyl terminus) domains. We have previously shown that NFBD1 is an early participant in DNA damage signaling pathways and that ionizing radiation-induced nuclear foci (IRIF) of NFBD1 colocalize with several DNA checkpoint signaling and repair factors. We report here that NFBD1 physically associates with ATM,
p53
, components of the MRE11-RAD50-NBS1 (MRN) complex, and gamma-H2AX. An overexpressed FHA domain-containing fragment of NFBD1 binds to endogenous NFBD1 and components of the MRN complex, but not to gamma-H2AX. This fragment interferes with IRIF formation by endogenous NFBD1, MRE11, or NBS1. A BRCT domain-containing fragment of NFBD1 binds to gamma-H2AX and
53BP1
, but not to components of the MRN complex, and abolishes IRIF formation by NFBD1, MRE11, NBS1,
53BP1
, CHK2 phospho-T68, gamma-H2AX, and possible ATM/ATR substrates recognized by anti-phospho-SQ/TQ antibody. These results suggest that NFBD1 is an ATM/ATR-dependent organizer that recruits DNA checkpoint signaling and repair proteins to the sites of DNA damage.
...
PMID:NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors. 1451 63
53BP1
interacts with the DNA-binding core domain of the
tumor suppressor p53
and enhances
p53
-mediated transcriptional activation. The
p53
-binding region of
53BP1
maps to the C-terminal BRCT domains, which are homologous to those found in the breast cancer protein BRCA1 and in other proteins involved in DNA repair. Here we compare the thermodynamic behavior of the BRCT domains of
53BP1
and BRCA1 and examine their ability to interact with the
p53
core domain. The free energies of unfolding are of similar magnitude, although slightly higher for
53BP1
-BRCT, and both populate an aggregation-prone partly folded intermediate. Interaction studies performed in vitro by analytical size-exclusion chromatography, analytical ultracentrifugation, and isothermal titration calorimetry reveal that
53BP1
-BRCT interacts with
p53
with a K(d) in the low micromolar range. Despite their homology with
53BP1
-BRCT domains, the BRCT domains of BRCA1 did not bind
p53
with any detectable affinity. In summary, although other studies have indicated that the BRCT domains of both BRCA1 and
53BP1
interact with
p53
core domain, the quantitative biophysical measurements performed here indicate that only
53BP1
can bind. Although both proteins may be involved in the same DNA repair pathways, our study indicates that a direct role in
p53
function is unique to
53BP1
.
...
PMID:Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. 1497 2
Many conventional anticancer treatments kill cells irrespective of whether they are normal or cancerous, so patients suffer from adverse side effects due to the loss of healthy cells. Anticancer insights derived from cell cycle research has given birth to the idea of cell cycle G2 checkpoint abrogation as a cancer cell specific therapy, based on the discovery that many cancer cells have a defective G1 checkpoint resulting in a dependence on the G2 checkpoint during cell replication. Damaged DNA in humans is detected by sensor proteins (such as hHUS1, hRAD1, hRAD9, hRAD17, and hRAD26) that transmit a signal via ATR to CHK1, or by another sensor complex (that may include gammaH2AX,
53BP1
, BRCA1, NBS1, hMRE11, and hRAD50), the signal of which is relayed by ATM to CHK2. Most of the damage signals originated by the sensor complexes for the G2 checkpoint are conducted to CDC25C, the activity of which is modulated by 14-3-3. There are also less extensively explored pathways involving
p53
, p38, PCNA, HDAC, PP2A, PLK1, WEE1, CDC25B, and CDC25A. This review will examine the available inhibitors of CHK1 (Staurosporin, UCN-01, Go6976, SB-218078, ICP-1, and CEP-3891), both CHK1 and CHK2 (TAT-S216A and debromohymenialdisine), CHK2 (CEP-6367), WEE1 (PD0166285), and PP2A (okadaic acid and fostriecin), as well as the unknown checkpoint inhibitors 13-hydroxy-15-ozoapathin and the isogranulatimides. Among these targets, CHK1 seems to be the most suitable target for therapeutic G2 abrogation to date, although an unexplored target such as 14-3-3 or the strategy of targeting multiple proteins at once may be of interest in the future.
...
PMID:G2 checkpoint abrogators as anticancer drugs. 1507 95
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>